Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2026 12:13 ET | Source: Faruqi & Faruqi LLP

SPRY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you...
August 06, 2026 07:00 ET | Source: GH Research PLC

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

Alignment with FDA on CMC and device plans for Phase 3Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estatePhase 2a results...
August 05, 2026 22:33 ET | Source: Braveheart Bio, Inc.

Braveheart Bio Announces Pricing of Upsized Initial Public Offering

SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic...
August 04, 2026 08:00 ET | Source: Healis Therapeutics

FDA clears Healis Therapeutics’ IND for Tyemvers®, Enabling U.S. Neuropsychiatric Trials

Healis Therapeutics opens IND, enabling first U.S. trials for Depression, PTSD, and neuropsychiatric disorders
July 30, 2026 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon to Report Q2 2026 Financial Results on August 6, 2026

VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...
July 29, 2026 06:30 ET | Source: MannKind

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MNKD Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety & Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
July 28, 2026 08:59 ET | Source: AGC Biologics, Inc.

AGC Biologics Lands Commercial Manufacturing Agreement for Yokohama Site Worth Hundreds of Millions of Dollars

Ahead of the official opening of AGC Biologics’ Yokohama site, a customer has already secured half of the facility’s manufacturing capacity.
July 27, 2026 14:14 ET | Source: Elevar Therapeutics

Elevar Therapeutics Announces Three Abstracts Accepted for Presentation at ESMO Congress 2026

FORT LEE, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
July 27, 2026 09:35 ET | Source: Moody Capital

Moody Capital Solutions to host the 2026 Disruptive Growth and Life Sciences Conference on Sep 9–10 in New York, NY

NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- via InvestorWire -- Moody Capital Solutions (“Moody Capital”), a relationship-driven investment bank committed to delivering high-touch, high-quality...
July 24, 2026 08:53 ET | Source: Neuraxpharm; Minoryx Therapeutics

NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease.